Jean-Francois Bergmann
Overview
Explore the profile of Jean-Francois Bergmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
148
Citations
2095
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Demoly P, Molimard M, Bergmann J, Delaisi B, Gouverneur A, Vadel J, et al.
Lancet Reg Health Eur
. 2024 Nov;
46:101120.
PMID: 39498359
[This corrects the article DOI: 10.1016/j.lanepe.2024.100915.].
2.
Demoly P, Molimard M, Bergmann J, Delaisi B, Gouverneur A, Vadel J, et al.
Lancet Reg Health Eur
. 2024 May;
41:100915.
PMID: 38707866
Background: The only disease-modifying treatment currently available for allergic rhinitis (AR) is allergen immunotherapy (AIT). The main objective of the EfficAPSI real-world study (RWS) was to evaluate the impact of...
3.
Devillier P, Molimard M, Bergmann J, Delaisi B, Gouverneur A, Vadel J, et al.
Expert Rev Clin Immunol
. 2023 Dec;
20(4):405-412.
PMID: 38112340
Background: The only causal treatment for allergic rhinitis (AR) is allergen immunotherapy (AIT) including personalized liquid sublingual AIT (SLIT). We present the methodology for establishing the EfficAPSI cohort to further...
4.
Gaujoux-Viala C, Bergmann J, Goguillot M, Melaine A, Guerin M, Edouard A, et al.
RMD Open
. 2023 Nov;
9(4).
PMID: 37914177
Objectives: The emergence of targeted therapy is changing rheumatoid arthritis (RA) management, but real-world data remain limited. This study aimed to describe real-world RA treatment patterns using data from a...
5.
Julian E, Pavlovic M, Sola-Morales O, Gianfrate F, Toumi M, Bucher H, et al.
Health Econ Rev
. 2022 Nov;
12(1):54.
PMID: 36333433
Objectives: Key challenges for a joint European Health Technology Assessment (HTA) include consolidated approaches towards the choice of adequate comparator(s), selection of endpoints that are relevant to patients with a...
6.
Julian E, Gianfrate F, Sola-Morales O, Mol P, Bergmann J, Salmonson T, et al.
Health Econ Rev
. 2022 Jun;
12(1):30.
PMID: 35652987
Objectives: We conducted a multi-stakeholder survey to determine key areas where a joint European health technology assessment (HTA) could provide 'additional benefit' compared to the status quo of many parallel...
7.
Sovaila S, Purcarea A, Froissart A, Ranque B, Kieffer P, Andres E, et al.
J Med Life
. 2020 Aug;
13(2):183-186.
PMID: 32742511
Clinical reasoning is the cornerstone of medical practice, and achieving this competence depends on a large number of factors. Internal medicine departments provide junior doctors with plentiful and varied patients,...
8.
Kopp A, Mangin O, Gantzer L, Lekens B, Simoneau G, Ravelomanantsoa M, et al.
Hum Vaccin Immunother
. 2020 May;
17(1):162-169.
PMID: 32429734
, the main cause of community-acquired pneumonia (CAP), also leads to exacerbations, hospitalizations, and mortality in chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF). The risk of CAP...
9.
Gaborit B, Bergmann J, Mussini C, Arribas J, Behrens G, Walmsley S, et al.
Lancet Infect Dis
. 2020 Apr;
20(10):1122-1123.
PMID: 32325035
No abstract available.
10.